<DOC>
	<DOCNO>NCT01485744</DOCNO>
	<brief_summary>LDE225 new medicine block Hedgehog ( Hh ) pathway . The Hh pathway cascade molecular event control cell growth link development many human cancer , include pancreatic cancer . Information research study suggest LDE225 combination FOLFIRINOX may help stop growth cancer cell . In research study , investigator look determine maximum dose LDE225 combination give safely patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>LDE225 With Fluorouracil , Leucovorin , Oxaliplatin , Irinotecan Untreated Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Study medication give cycle 14 day . Subjects keep study drug diary treatment cycle . LDE225 capsule take mouth morning every day cycle . On day 1-2 cycle , subject take LDE225 clinic follow FOLFIRINOX intravenous infusion ( vein ) . Subjects come clinic weekly first 5 week , every week ( Week 7 , 9 , 11 , etc . ) receive follow procedure : Review current medication side effect Physical exam Performance Status Blood test ( 2 teaspoon blood ) Assessment tumor ( repeat every 8 week ) ECG week 3 5 Subjects also pharmacokinetic ( PK ) blood sample take . PK sample use find amount study medication blood . Each PK sample 1/2 teaspoon blood . Subjects PK sample take : Day 1 Cycles 1 , 2 , 3 , 4 , 6 , 7 dose LDE225 Day 1 Cycle 5 - drawn first dose LDE225 1 , 2 , 3 , 4 , 5 , 6 hour Day 2 Cycle 5 : One PK blood sample</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic pancreatic adenocarcinoma Previously untreated locally advanced metastatic pancreatic adenocarcinoma . Pts newly diagnose metastatic recurrence adjuvant therapy resect disease eligible , completion adjuvant therapy &gt; 8 month ago Measurable disease Adequate organ marrow function Able take oral drug Concurrent active primary metastatic cancer superficial squamous cell basal cell skin cancer Pregnant breastfeed Receiving standard investigation anticancer agent , exception hormonal therapy Prior chemoradiation primary pancreatic tumor unless measurable distant site disease Known CNS metastases History hypersensitivity reaction component treatment regimen Known malabsorption syndrome Neuromuscular disorder Receiving antineoplastic therapy concurrently Requires warfarin/Coumadin therapeutic coagulation Receiving treatment medication know moderate strong inhibitor inducer CYP3A4/5 Uncontrolled diarrhea Peripheral neuropathy &gt; grade 1 due cause Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia chronic atrial fibrillation , psychiatric illness/social situation would limit compliance study requirement HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>untreated</keyword>
	<keyword>advanced</keyword>
</DOC>